Physical activity and mental well-being during COVID-19 pandemic

The corona virus disease 2019 (COVID-19) pandemic has resulted in most nations deciding upon self-isolation and social distancing policies for their citizens to control the pandemic and reduce hospital admission. This review aimed at evaluating the effect of physical activity on mental well-being during the COVID-19 pandemic. It was concluded that the COVID-19 pandemic may lead to augmented levels of angiotensin-converting enzyme (ACE)-2 that led to cardiovascular and neurological disorders associated with highly inflammatory effects of viral infection affecting the brain tissues leading to damage of the nervous system and resulting in cognition dysfunction, insulin sensitivity reduction, and behavioral impairments. Anxiety and depression may lead to negative effects on various quality of life domains, such as being physically inactive. Regular physical activities may reduce inflammatory responses, improve ACE-2 responses, and improve mental well-being during self-isolation and social distancing policies related to the COVID-19 pandemic. Further studies should be conducted to assess the different intensities of physical activities on cardiovascular function, and mental well-being during the COVID-19 pandemic.     

Pleomorphic mastocytoma associated with loss of chromosome 5, PDGFRA,and HRAS mutations: A case of cutaneous mastocytosis with severe atypia and indolent behavior

A 21‐year‐old female presented with a 5‐year history of an erythematous papule on her right breast. The biopsy showed a dense, dermal nodular infiltrate, extending focally into the subcutaneous tissue. The infiltrate was composed predominantly of pleomorphic cells with bi‐lobed, multi‐lobed, horseshoe, or ring‐shaped nuclei. There was a smaller subset of monomorphous cells characterized by a round, reniform, or elongated single‐lobed nucleus. Accompanying cells included few foamy histiocytes, lymphocytes, and numerous scattered eosinophils. No necrosis, vascular invasion, or ulceration was present. The pleomorphic and monomorphic granular cells were positive for Giemsa stain as well as for tryptase, CD117, CD68, CD2, and CD30 immunohistochemistry and negative for S100, CD1a, myeloperoxidase, lysozyme, and CD56. Clinical examination was negative for any additional similar lesions and serum tryptase was within normal limits. The bone marrow was not biopsied. In addition, fluorescent in situ hybridization revealed multiple clones with loss of number 5 chromosome and PDGFRA and HRAS mutations. The lesion did not recur or progress after a 6‐year clinical follow‐up. To our full knowledge, we report the first case of pleomorphic mastocytoma with loss of chromosome 5 and PDGFRA and HRAS mutations.     

Organ-based tube current modulation in chest CT. A comparison of three vendors

IntroductionOrgan-based tube current modulation (OBTCM) is designed for anterior dose reduction in Computed Tomography (CT). The purpose was to assess dose reduction capability in chest CT using three organ dose modulation systems at different kVp settings. Furthermore, noise, diagnostic image quality and tumour detection was assessed.MethodsA Lungman phantom was scanned with and without OBTCM at 80–135/140 kVp using three CT scanners; Canon Aquillion Prime, GE Revolution CT and Siemens Somatom Flash. Thermo-luminescent dosimeters were attached to the phantom surface and all scans were repeated five times. Image noise was measured in three ROIs at the level of the carina. Three observers visually scored the images using a fivestep scale. A Wilcoxon Signed-Rank test was used for statistical analysis of differences.ResultsUsing the GE revolution CT scanner, dose reductions between 1.10 mSv (12%) and 1.56 mSv (24%) (p < 0.01) were found in the anterior segment and no differences posteriorly and laterally. Total dose reductions between 0.64 (8%) and 0.91 mSv (13%) were found across kVp levels (p < 0.00001). Maximum noise increase with OBTCM was 0.8 HU. With the Canon system, anterior dose reductions of 6–10% and total dose reduction of 0.74–0.76 mSv across kVp levels (p < 0.001) were found with a maximum noise increase of 1.1 HU. For the Siemens system, dose increased by 22–51% anteriorly; except at 100 kVp where no dose difference was found. Noise decreased by 1 to 1.5 HU.ConclusionOrgan based tube current modulation is capable of anterior and total dose reduction with minimal loss of image quality in vendors that do not increase posterior dose.Implications for practiceThis research highlights the importance of being familiar with dose reduction technologies.     

Non-EPI versus Multishot EPI DWI in Cholesteatoma Detection: Correlation with Operative Findings

BACKGROUND AND PURPOSE:Although multishot EPI (readout-segmented EPI) has been touted as a robust DWI sequence for cholesteatoma evaluation, its efficacy in disease detection compared with a non-EPI (eg, HASTE) technique is unknown. This study sought to compare the accuracy of readout-segmented EPI with that of HASTE DWI in cholesteatoma detection.MATERIALS AND METHODS:A retrospective review was completed of consecutive patients who underwent MR imaging for the evaluation of suspected primary or recurrent/residual cholesteatomas. Included patients had MR imaging examinations that included both HASTE and readout-segmented EPI sequences and confirmed cholesteatomas on a subsequent operation. Two neuroradiologist reviewers assessed all images, with discrepancies resolved by consensus. The ratio of signal intensity between the cerebellum and any observed lesion was noted.RESULTS:Of 23 included patients, 12 (52.2%) were women (average age, 47.8 [SD, 25.2] years). All patients had surgically confirmed cholesteatomas: Six (26.1%) were primary and 17 (73.9%) were recidivistic. HASTE images correctly identified cholesteatomas in 100.0% of patients. On readout-segmented EPI sequences, 16 (69.6%) were positive, 5 (21.7%) were equivocal, and 2 (8.7%) were falsely negative. Excellent interobserver agreement was noted between reviews on both HASTE (κ = 1.0) and readout-segmented EPI (κ = 0.9) sequences. The average signal intensity ratio was significantly higher on HASTE than in readout-segmented EPI, facilitating enhanced detection (mean difference 0.5; 95% CI, 0.3–0.8; P = .003).CONCLUSIONS:HASTE outperforms readout-segmented EPI in the detection of primary cholesteatoma and disease recidivism.

Middle ear cholesteatomas are ectopic, keratinizing squamous epithelium, which may be acquired or, much less commonly, congenital.^1,2 Although not considered a true neoplasm, cholesteatomas are locally destructive and have a high propensity for recurrence following surgical removal. As they gradually expand, cholesteatomas erode the osseous structures within and adjacent to the middle ear cavity, including the ossicles, labyrinth, fallopian canal, and middle fossa bone plate.³ Current mainstay therapy includes microsurgical extirpation, with the chief goal of complete disease removal and prevention of intratemporal and intracranial complications.⁴ The most common microsurgical approach for cholesteatoma is an canal wall up tympanomastoidectomy, in which the posterior bony ear canal is left intact and the tympanic membrane is reconstructed. Depending on the extent of disease at surgery, a planned second-look procedure may be performed approximately 1 year after the initial operation to evaluate residual disease and potentially reconstruct the ossicular chain when indicated. Nevertheless, residual and/or recurrent (ie, recidivism) disease occurs in up to 30% of cases. Imaging is crucial in cholesteatoma management; it aids in the initial diagnosis and may obviate the need for second-look surgery.^5,6During the past decade, DWI has emerged as a powerful diagnostic tool for detection of both primary and residual or recurrent cholesteatomas.^7-9 Cholesteatomas demonstrate marked hyperintensity on DWI , likely related to either T2 shinethrough or intralesional restricted diffusion related to keratin debris.¹⁰ Across the years, there have been many iterations of DWI optimization for cholesteatoma identification. The EPI trajectory used by conventional DWI makes such sequences prone to substantial susceptibility artifacts, and single-shot EPI sequences were found to be poor at identifying lesions of <4–5 mm.^11-13 Consequently, non-EPI DWI techniques began to be favored; such algorithms minimize susceptibility artifacts and geometric distortion related to the skull base and are able to detect lesions as small as 2 mm.^14,15 BLADE (Siemens) and other such PROPELLER sequences are subtypes of non-EPI techniques that minimize susceptibility artifacts and geometric distortions by sampling k-space in a rotating fashion.^16,17More recently, HASTE DWI (Siemens) has emerged as a particularly effective sequence, which is relatively insensitive to motion and has been shown in prior studies to detect cholesteatomas with promising accuracy.^18,19 Although traditional EPI techniques have been largely abandoned in the setting of cholesteatoma detection, readout-segmented EPI (RESOLVE; Siemens) DWI is a relatively new technique that has been promoted as a possible alternative diffusion sequence. RESOLVE is a multishot (MS) EPI sequence that is able to reduce geometric distortions at the expense of longer imaging time. Recent reports have indicated that RESOLVE may be a useful sequence in cases of suspected cholesteatoma.^7,20Despite its proposed efficacy in cholesteatoma imaging, the diagnostic utility of RESOLVE sequences has yet to be robustly evaluated against non-EPI DWI, the current criterion standard. Thus, this study was conceived with the chief goal of assessing the accuracy of RESOLVE in the detection of cholesteatomas and comparing the ability of RESOLVE with that of HASTE sequences in this context.     

Elevated serum uric acid is a predictor of contrast associated acute kidney injury in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

BackgroundContrast associated-acute kidney injury (CA-AKI) has been associated with adverse outcomes after ST-segment elevation myocardial infarction (STEMI). However, early markers of CA-AKI are still needed to improve risk stratification. We investigated the association between elevated serum uric acid (eSUA) and CA-AKI in patients with STEMI treated with primary percutaneous coronary intervention (pPCI).Methods and resultsSerum creatinine (Scr) was measured at admission and 24, 48 and 72 h after pPCI. CA-AKI was defined as an increase of 25% (CA-AKI 25%) or 0.5 mg/dl (CA-AKI 0.5) of Scr level above the baseline after 48 h following contrast administration. Multivariable analyses to investigate CA-AKI predictors were performed by binary logistic regression and multivariable backward logistic regression model.In the 3023 patients considered, CA-AKI was more frequent among patients with eSUA as compared with patients with normal SUA levels, considering both CA-AKI definitions (CA-AKI25%: 20.8% vs 16.2%, p < 0.012; CA-AKI 0.5: 10.1% vs 5.8%, p < 0.001). The association between eSUA and CA-AKI was confirmed at multivariable analyses (CA-AKI 25%: odd ratio 1.32, 95% CI 1.03–1.69, p = 0.027; CA-AKI 0.5: odd ratio 1.76, 95% CI 1.11–2.79, p = 0.016).ConclusionElevated serum uric acid is associated with CA-AKI after reperfusion in patients with STEMI treated with pPCI.